Notiretatug rezetecan

瑞康诺替妥塔单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameNotiretatug rezetecan
Drug Alias NameSHR-A2102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker +[4] 
Mechanisms of ActionAnti-NECTIN4DNA topoisomerase I inhibitors
TargetsNectin-4DNA topoisomerase I
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Hengrui Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHenan Provincial Cancer HospitalFudan UniversityShanghai Hengrui Pharmaceutical Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Neoplasms +[12] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A